

ProteoTech's CEO to Present at the 8th Annual Congress of International Drug Discovery Sciences and Technology— October 26, 2010

ProteoTech, Inc. today announced that the Company's Chief Executive Officer, Steve Runnels, will Chair the sessions on International Partnering and will also present at the 8th Annual International Congress of Drug Discovery Sciences and Technology.

The title of Mr. Runnels' presentation on Tuesday, October 26, 2010 at 9:20am is:

*The Wisdom of Early Stage Partnering for
Both Small and Large Pharma Companies*

Mr. Runnels' presentation will be held at the Beijing International Convention Center (BICC), Beijing, China. Website: <http://www.iddst.com/2010>.

About ProteoTech: ProteoTech is a private drug development company founded in 1996 located in the Seattle, WA area (Kirkland, WA), and is focused on targeting amyloid diseases. Besides EXEBRYL-1[®] for Alzheimer's disease treatment, the Company is also in late stage pre-clinical development of *Synucleire*[™] for the treatment of Parkinson's disease, Systebryl[™] for the treatment of Systemic Amyloidosis, and is in late stage pre-clinical development for a novel small peptide called PeptiClere[™] for the treatment of Alzheimer's disease. For more information please see the Company web site at www.proteotech.com.